Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma: Committee papers
Cited by National Institute for Health and Care Excellence on
The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.